Broadlane cuts deals with R2 and Varian

Article

Provider of cost management services Broadlane has designated R2 Technology as its exclusive provider of computer-aided detection systems. The company also cut a three-year agreement with Varian Medical Systems for the supply of radiotherapy systems. The

Provider of cost management services Broadlane has designated R2 Technology as its exclusive provider of computer-aided detection systems. The company also cut a three-year agreement with Varian Medical Systems for the supply of radiotherapy systems. The exclusive agreement with R2, which extends to Dec. 31, 2004, provides access for Broadlane customers to R2's ImageChecker CAD mammography system. Varian will offer Broadlane institutions a range of radiotherapy products including its Clinac medical linear accelerators, Millennium multileaf collimators, and PortalVision electronic portal imaging systems. Broadlane customers will also have access to imaging products from GE Medical Systems that Varian distributes in North America under a special See and Treat Cancer Care partnership agreement.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.